Edwards Lifesciences Reports Second Quarter Results
Edwards Lifesciences reported a 13.6% increase in Q2 sales, reaching $1.74 billion. TAVR sales rose by 11.3% to $1.26 billion while TMTT sales were $195.9 million. The company posted an EPS of $0.42, with adjusted EPS at $0.78, supported by recent clinical data at New York Valves.
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas